ArticleProceedings of the National Academy of Sciences of the United States of America2023
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing.
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 46 citations in OpenAlex.
- Long-read sequencing reveals widespread novel splicing and neojunction-derived neoantigens in nasopharyngeal carcinoma.Genome research · 2026Article
- PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer.EMBO molecular medicine · 2026Article
- Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- Decoding neoantigen-encoding tumor-specific transcripts unveils a shared target reservoir for immunotherapy in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design.ArXiv · 2026Article
- The emerging roles of alternative splicing in modulating tumor immune responses and immunotherapies.Cell death and differentiation · 2026Review
- Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.Molecular diagnosis & therapy · 2026Review
- Splitpea: a Python package for protein-protein interaction network rewiring analysis due to alternative splicing.Bioinformatics (Oxford, England) · 2026Article
- Review
- Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- ImmunoPepper: extracting personalized peptides from complex splicing graphs.Bioinformatics (Oxford, England) · 2026Article
- Targeting splicing-derived neoantigens for precision cancer immunotherapy.Frontiers in immunology · 2026Review
- Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.Frontiers in immunology · 2026Review
- mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Transcriptome-wide Mendelian randomization and single-cell analysis during CD4NPJ precision oncology · 2025Article
- Targeting the roots of myeloid malignancies with T cell receptors.Nature reviews. Cancer · 2025Review
- Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.Biomarker research · 2025Review
- Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?Journal of hematology & oncology · 2025Review
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas.Cell reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 2 institutions in 1 country.
Yang PanBioinformatics Interdepartmental Graduate Program, University of California, Los Angeles, CA 90095.
John W PhillipsDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
Beatrice D ZhangCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0003-1636-600X
Miyako NoguchiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
Eric KutscheraCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0002-2160-1820
Jami McLaughlinDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
Pavlo A NesterenkoMolecular Biology Institute, University of California, Los Angeles, CA 90095.ORCID 0000-0001-9841-8170
Zhiyuan MaoDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Nathanael J BangayanDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Robert WangCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Wendy TranDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
Harry T YangBioinformatics Interdepartmental Graduate Program, University of California, Los Angeles, CA 90095.ORCID 0000-0001-9125-5962
Yuanyuan WangBioinformatics Interdepartmental Graduate Program, University of California, Los Angeles, CA 90095.
Yang XuCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Matthew B ObusanDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.ORCID 0000-0002-9579-2308
Donghui ChengEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
Alex H LeeDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Kathryn E Kadash-EdmondsonCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Ameya ChamphekarDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Cristina Puig-SausDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.ORCID 0000-0002-3014-3649
Antoni RibasDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.ORCID 0000-0003-3669-8458
Robert M PrinsDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Christopher S SeetMolecular Biology Institute, University of California, Los Angeles, CA 90095.
Gay M CrooksEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
Owen N WitteDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.ORCID 0000-0003-4461-4533
Yi XingCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104.
University of California, Los Angeles · USChildren's Hospital of Philadelphia · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MNCI NIH HHS P50 CA211015
Abstract
Alternative splicing (AS) is prevalent in cancer, generating an extensive but largely unexplored repertoire of novel immunotherapy targets. We describe
Indexed as
NeoplasmsRNA PrecursorsAlternative SplicingAntigens, NeoplasmEpitopes, T-LymphocyteHumansImmunotherapyLeukocytes, MononuclearMalePeptidesReceptors, Antigen, T-CellAntigens, NeoplasmEpitopes, T-LymphocytePeptidesReceptors, Antigen, T-CellRNA PrecursorsimmunotherapyRNA splicingT cell receptors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.